Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical)

重组抗VEGFR2全人源单抗（四川科伦博泰生物医药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRamucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical)
Drug Alias Name雷莫芦单抗生物仿制药（四川科伦博泰生物医药）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan Kelun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms

Other Information

ATC CodeL01XC21
Related LinksN/A